ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) shares rose 6.1% during mid-day trading on Wednesday . The stock traded as high as $19.91 and last traded at $19.85. Approximately 2,397,523 shares traded hands during trading, a decline of 28% from the average daily volume of 3,320,496 shares. The stock had previously closed at $18.71.
Analyst Ratings Changes
Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.
Check Out Our Latest Stock Report on ADMA Biologics
ADMA Biologics Trading Up 0.8 %
The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock's 50 day moving average is $16.76 and its 200-day moving average is $18.04. The company has a market capitalization of $4.68 billion, a P/E ratio of 70.71 and a beta of 0.60.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its stake in shares of ADMA Biologics by 4.2% in the 4th quarter. California State Teachers Retirement System now owns 217,391 shares of the biotechnology company's stock valued at $3,728,000 after purchasing an additional 8,717 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at $225,000. Mackenzie Financial Corp grew its position in shares of ADMA Biologics by 212.2% in the 4th quarter. Mackenzie Financial Corp now owns 74,539 shares of the biotechnology company's stock worth $1,278,000 after buying an additional 50,660 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of ADMA Biologics in the 4th quarter worth about $85,000. Finally, Neo Ivy Capital Management lifted its position in ADMA Biologics by 512.6% during the 4th quarter. Neo Ivy Capital Management now owns 297,627 shares of the biotechnology company's stock valued at $5,104,000 after acquiring an additional 249,043 shares during the period. Institutional investors own 75.68% of the company's stock.
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
